Overexpression and clinical significance of IBP in epithelial ovarian carcinoma

Xu, Yingjuan; Hou, Yangming; Liu, Tianbo; Lou, Ge

doi:10.3892/ol.2018.8125

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, DEF6 selectively binds to Rac1 to regulate cell morphology (14). These data indicate that DEF6 serves a key role in cancer metastases (22,39). Consistent with these results, the current study demonstrated that DEF6 significantly promoted motility and MMP9 expression in OS cells.…”

Section: Discussionsupporting

confidence: 87%

Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma

et al. 2020

View full text Add to dashboard Cite

Metastasis is the primary cause of high mortality in patients with osteosarcoma (OS). However, the molecular mechanisms underlying the regulation of metastatic disease are yet to be determined. Differentially expressed in FDCP 6 homolog (DEF6) has been demonstrated to be correlated with the metastatic behavior of several cancers, such as breast, ovarian and colorectal cancers. However, the role of DEF6 in OS remains unknown. Accordingly, the current study aimed to investigate the relationship between DEF6 expression and the malignant behavior of OS. The results revealed that high levels of DEF6 in OS tissues were associated with advanced clinical stage and metastases. Furthermore, immunohistochemistry results predicted a poor prognosis in 58 human OS specimens. Additionally, DEF6 expression was reported to be upregulated in human OS cell lines compared with a normal osteoblast cell line. small interfering RNA transfection, cell proliferation and colony formation assays, wound healing assays and Transwell assays were performed. DEF6 was not identified to be a major driver of OS cell proliferation, but it significantly contributed to metastatic potential in vitro. In addition, bioinformatics, western blotting and immunohistochemistry results indicated that MMP9 expression was positively correlated with DEF6 expression in human OS. To summarize, the results revealed that increased levels of DEF6 were associated with metastasis and poor prognosis in human OS and that DEF6 expression is positively correlated with MMP9 expression. The results indicated that DEF6 may serve as a potential antimetastatic target for OS.

show abstract

Section: Discussionsupporting

confidence: 87%

Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…More importantly, as a GEF, DEF6 can activate genes from the Rho-GTPase family, which contribute to tumor proliferation, migration and invasion (19). Previous studies have indicated that high expression levels of DEF6 predict a poor prognosis for colorectal cancer, ovarian carcinoma and breast cancer (20)(21)(22). It has also been demonstrated that there are high expression levels of DEF6 in RCC (23).…”

Section: Introductionmentioning

confidence: 99%

High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma

Zhu

Lin

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignant tumors and early detection contributes to a better prognosis. Finding new biomarkers for the diagnosis or treatment remains meaningful. DEF6 guanine nucleotide exchange factor (DEF6) is upregulated in ccRCC compared to normal controls, but the relationship between DEF6 expression and prognosis in ccRCC is unclear. Moreover, the potential biological functions of DEF6 in ccRCC remains unclear. In the present study, the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), TISIDB and the clinical database of the Peking University First Hospital were used to analyze DEF6 expression in ccRCC. Immunohistochemistry (IHC), western blotting and reverse transcription-quantitative PCR were used to examine the DEF6 protein and mRNA expression levels in cell lines and clinical samples. Subsequently, the Kaplan-Meier method and Cox regression analyses were used to determine the impact of DEF6 expression on the overall survival of patients alongside other clinical variables in both the TCGA database and the present clinical database. The results showed that both DEF6 mRNA and protein expression levels were upregulated in ccRCC compared to normal controls. The Kaplan-Meier survival analysis showed that patients with high DEF6 expression had poor prognoses from both the TCGA database and the present clinical database. Univariate survival analysis and multivariate survival analysis revealed that DEF6 could be an independent prognostic factor for ccRCC. Additionally, bioinformatics analysis indicated that differentially expressed genes related to DEF6 expression influenced ccRCC by regulating the tumor immune microenvironment. In conclusion, overexpression of DEF6 is significantly correlated with a poor prognosis for patients with ccRCC and DEF6 may influence the biological processes involved with ccRCC by regulating the immune microenvironment.

show abstract

Overexpression and clinical significance of IBP in epithelial ovarian carcinoma

Cited by 2 publications

References 31 publications

Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma

Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma

High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma

Contact Info

Product

Resources

About